Camizestrant Combination Reduced Risk of First and Second Disease Progression in ESR1-Mutant Advanced HR-Positive Breast Cancer in SERENA-6 AstraZeneca has announced updated positive findings from its pivotal Phase III SERENA-6…
Iza-Bren Significantly Improves Overall and Progression-Free Survival in Triple-Negative Breast Cancer and Esophageal Cancer SystImmune, Inc., a clinical-stage biotechnology company focused on developing innovative cancer therapies, and Bristol Myers Squibb…
Hims & Hers Completes Acquisition of Eucalyptus, Strengthening Clinically Supported Weight Management Services in Germany Hims & Hers Health, Inc. has officially completed its acquisition of Eucalyptus, the parent company…
Incyte Reports Positive Phase 3 frontMIND Results for Tafasitamab Plus Lenalidomide Added to R-CHOP in First-Line DLBCL and HGBL Incyte Corporation (Nasdaq: INCY) has announced positive results from the pivotal…
C2N Diagnostics and SouthGenetics Partner to Expand Access to Alzheimer’s Blood Biomarker Testing Across Latin America and the Caribbean C2N Diagnostics, LLC, a specialty diagnostics company focused on advancing blood-based…
Corsair Pharma Reports Successful Phase 1 Results for TRX-248 Transdermal System in Pulmonary Arterial Hypertension Corsair Pharma, Inc., a private biopharmaceutical company focused on innovative drug delivery technologies, has announced…
Integrated DNA Technologies Introduces End-to-End Oncology Research Workflows Optimized with Illumina, Inc. Software for Faster Insights Integrated DNA Technologies (IDT), a Danaher company and a global leader in genomics solutions,…
Shionogi’s XOCOVA® Becomes First FDA-Approved Oral Treatment for Preventing COVID-19 Following Exposure Shionogi & Co., Ltd. has announced a significant regulatory milestone for its antiviral medicine XOCOVA® (ensitrelvir), with the…
Avenzo Reports Updated Phase 1 Data for AVZO-021 Showing Clinical Activity and Favorable Tolerability in Heavily Pretreated HR+/HER2- Breast Cancer Avenzo Therapeutics has announced updated clinical findings from the Phase…
Rallybio and Avenzo Therapeutics Announce Merger Backed by $215 Million Financing to Advance Next-Generation Oncology Pipeline Rallybio Corporation and Avenzo Therapeutics have entered into a definitive merger agreement that will…
Novel Blood Test Reveals Key Tumor Microenvironment Signals Predictive of Immunotherapy Outcomes in Sarcoma Aqtual, Inc., a precision medicine company focused on developing advanced cell-free DNA (cfDNA) diagnostics for oncology…
Qurient Doses First Patient in Phase 2 Trial of Mocaciclib for CDK4/6 Inhibitor-Resistant HR-Positive Breast Cancer Qurient Co., Ltd. has announced a major clinical development milestone with the dosing of…